King Minos II hall
Hereditary nephropathies
Hereditary nephropathies
N.1A. Polycystic kidney disease
1. Safety and effectiveness of Tolvaptan Pavlos Anassis
2. New KDIGO Guidelines Vasileios Kolovos
3. Genetic tests: what should I know? Anastasios Fountoglou
N.2A. Other hereditary nephropathies
1. Fabry Disease: what should I know? Vaia Raikou
2. Type-4 collagen gene mutation related nephropathies Irini Katsipi
3. Hereditary tubulointerstitial nephropathies Ioannis Tzanakis
Cardiovascular morbidity
Hereditary nephropathies
Coffee break
N.3A. Cardiovascular morbidity in CKD
1. Treatment on hyperlipidaemia: what's new? Ioannis Droulias
2. HIF inhibitors: their place in clinical practice Athena Gompou
3. Update in the management of hyperkalaemia Evdokia Efthymiou
Clinical Nephrology
Hereditary nephropathies
Coffee break
N.4A. IgA nephropathy
1. The role of B cells and BAFF/APRIL Dimitrios Bakoulis
2. New and emerging therapies in IgA nephropathy Panagiotis Kompotiatis
3. How should I manage the patient with IgA nephropathy Maria Stangou
Lunch
General assembly
Hypertension
Hereditary nephropathies
N.6A. Hypertension
1. Management of hypertension in patients with CKD Georgios Hatzivasiliou
2. Resistant hypertension Vasileios Raptis
3. Use of diuretics in CKD: benefits and risks Eleni Intzevidou
4. Hypertension in dialysis Antonios Zagorianakos
Hereditary nephropathies
Breakthrough in Nephrology
Coffee break
N.5A. Changing the status quo in CKD
1. SGLT2 inhibitors: what's new? Dimitrios Vlahakos
2. The place of GLP-1 agonists in clinical practice Petros Kalogeropoulos
3. The place of MRAs in clinical practice Konstantinos Psounis
Obesity: chronic disease and axeses
State of the art lecture
Hereditary nephropathies
Coffee break
Haemodialysis
Hereditary nephropathies
N.7A. Haemodialysis
1. Uremic pruritus: systematic review, evaluation and management Olga Ellina
2. Response to ultrafiltration in dialysis Nikolaos Mitsides
3. Management of the patient with diabetes on dialysis Irini Vasiliou
Close
Approved by:
Participants:
Participants:
